Treatment of Malignant Tumors With NK Cell

NCT ID: NCT05143125

Last Updated: 2021-12-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-05
• Study Completion Date: 2024-02-29

Brief Summary

Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%.

Detailed Description

Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%. However, NK cell therapy alone or the use of autologous NK cells to treat solid tumors is not effective. In clinical trials related to rectal cancer, esophageal cancer, kidney cancer, and gastric cancer, the clinical response of NK cell adoptive therapy is not good. A phase II clinical study found that the disease control rate of patients with ovarian cancer and breast cancer after radiotherapy and chemotherapy can reach about 60% by NK cell infusion. The main reason for the low treatment efficiency of solid tumors is related to the immunosuppressive effect of the tumor microenvironment. Combination therapy is a potential breakthrough. Researches targeting tumor immune microenvironment, targeting tumor cells and combined with NK cell therapy have shown tumor therapeutic potential. NK cells combined with IgG1 antibody treatment of gastric cancer and colon cancer in about 50% of patients with partial remission, and 17% of patients are in stable condition. In summary, the combined application of the demethylation drug DAC and NK cell infusion may be a new clinical strategy for the treatment of malignant tumors.

Conditions

Malignancy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Treatment group

Decitabine combined with NK cell infusion as post-remission therapy

Group Type: EXPERIMENTAL

Decitabine combined with NK cell infusion

Intervention Type: BIOLOGICAL

Decitabine combined with NK cell infusion

Interventions

Decitabine combined with NK cell infusion

Decitabine combined with NK cell infusion

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged 18-70 (including 18 and 70 years old);

2. Those who have been diagnosed as malignant tumor by pathological and histological examination, have received anti-tumor treatment and are in remission;

3. The ECOG score of the patient is less than 2 points;

4. The patient did not receive any chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) and other anti-tumor treatments within 4 weeks before enrollment, and his previous treatment-related toxicity had returned to grade <1 (hair loss, peripheral nerves) at the time of enrollment Except for low-level toxicity such as inflammation);

5. The patient's intravenous access is unobstructed, which can meet the needs of intravenous drip;

6. The patient voluntarily participates and signs an informed consent form, and follows the research treatment plan and visit plan.

Exclusion Criteria

1. The patients used high-dose hormones within 1 week before enrollment (except for patients using inhaled hormones);

2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies;

3. Patients who have been treated with other cellular immune products (DC, T, CTL, CAR-T, etc.);

4. The patient had an uncontrollable infection within 4 weeks before enrollment;

5. Active B HBV DNA>1000copy/mL/C virus hepatitis (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive;

6. The patient has participated in other clinical studies within 6 weeks before enrollment;

7. Patients suffering from mental illness;

8. The patient has drug abuse/addiction and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results;

9. The patient has alcohol dependence;

10. Women who are pregnant (positive urine/blood pregnancy studies) or breastfeeding; men or women who have a pregnancy plan within the past year; patients cannot be guaranteed to take effective contraceptive measures during the study period;

11. According to the judgment of the investigator, the patient has other conditions that are not suitable for enrollment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shenzhen University General Hospital

OTHER

Sponsor Role: lead

Responsible Party

YuLi

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Li Yu, Dr

Role: PRINCIPAL_INVESTIGATOR

Shenzhen University General Hospital

Locations

Shenzhen University General hospital

Shenzhen, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Li Yu, Dr

Role: CONTACT

Phone: +8675521839178

Email: liyu@vip.163.com

Facility Contacts

Shujiao He, Dr

Role: primary

Other Identifiers

HEM-ONCO-009

Identifier Type: -

Identifier Source: org_study_id